Trial · NCT05914155
Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic Syndrome
NCT05914155, Phase 3, Active not recruiting, Shoichi Maruyama MD PhD
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic Syndrome. Trials, record NCT05914155. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05914155
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic Syndrome
- NCT number
- NCT05914155
- Status
- Active not recruiting
- Phases
- Phase 3
- Enrollment
- 88 participants, estimated
- Lead sponsor
- Shoichi Maruyama MD PhD
- Conditions
- Glomerulonephritis, Membranous, Nephrotic Syndrome，Idiopathic
- Interventions
- Rituximab (genetical recombination), Placebo, Rituximab (genetical recombination)
- First posted
- 2023-06-22
- Last updated
- 2026-08-12
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of patients achieving ICR I | up to 26 weeks | Achieving ICR I is defined as "Urine protein-creatinine ratio \< 1.0 g/gCr". |
| Secondary | Percentage of patients who are CR, ICR I, ICR II, NR or PR | up to 26 weeks | CR, ICR I, ICR II, NR or PR are defied as below; CR (Complete Remission): Urine protein-creatinine ratio \< 0.3 g/gCr ICR I (Incomplete Remission Type I): 0.3 g/gCr ≤ Urine protein-creatinine ratio \< 1.0 g/gCr ICR II (Incomplete Remission Type II): 1.0 g/gCr ≤ Urine protein-creatinine ratio \< 3.5 g/gCr NR (No Response): 3.5 g/gCr ≤ Urine protein-creatinine ratio PR (Partial Remission): Decrease in urine protein-creatinine ratio from base line ≥50%, and urine protein-creatinine ratio 0.3 to 3.5 g/gCr |
| Secondary | Duration before achieving CR, ICR I, ICR II or PR | up to 26 weeks | Duration of achieving CR, ICR I, ICR II or PR is summarized. |
| Secondary | Urine protein-creatinine ratio | up to 26 weeks | The differences of urine protein-creatinine ratio between prior to treatment and at each timepoint are summarized. |
| Secondary | eGFR | up to 26 weeks | The differences of eGFR between prior to treatment and at each timepoint are summarized. |
| Secondary | B-cells (CD19-positive and CD20-positive cells) | up to 26 weeks | B cell counts (CD19 positive and CD20 positive cell counts) at each timepoint are summarized. |
| Secondary | Expression of HACA | up to 26 weeks | The number of patients expressing HACA, and the proportion of these patients at each timepoint are summarized. |
| Secondary | Serum rituximab (genetical recombination) concentration | up to 26 weeks | Serum rituximab (genetical recombination) level at each timepoint are summarized. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05914155
GET https://conductscience.org/api/trials/v1/NCT05914155/registered